logo.png
AEON Biopharma Appoints Dr. Chad K. Oh as Chief Medical Officer to Lead Clinical Development of ABP-450 Across Several Therapeutic Indications
June 09, 2021 08:00 ET | AEON Biopharma
NEWPORT BEACH, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of therapeutic indications for its...
logo.png
AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia
April 05, 2021 08:00 ET | AEON Biopharma
NEWPORT BEACH, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc., a private clinical-stage biopharmaceutical company focused on the development of therapeutic indications for its...
logo.png
AEON Biopharma Initiates Enrollment in Phase 2 Trial of ABP-450 for the Preventive Treatment of Migraine
March 08, 2021 16:01 ET | AEON Biopharma
-Clinical trial will enroll both episodic and chronic migraine patients- -Protocol utilizes streamlined treatment paradigm with fewer injections- -Topline data expected in mid-2022- NEWPORT BEACH,...
logo.png
AEON Biopharma Announces FDA Acceptance of IND for ABP-450 as a Treatment for Cervical Dystonia; Secures $25 Million Investment
September 02, 2020 16:01 ET | AEON Biopharma
-Critical milestone transitions AEON Biopharma to clinical-stage company- -Moving directly into Phase 2 clinical trial expected to begin in the first half of 2021- -Investment expected to provide...